• 1. Excellent peroxidase mimicking property of CuO/Pt nanocomposites and their application as an ascorbic acid sensor?
  Xinhuan Wang,Shuangfei Cai,Cui Qi Analyst, 2017,142, 2500-2506
• 2. Evolution of dealloying induced strain in nanoporous gold crystals?
  Ross Harder,David C. Dunand,Ian McNulty Nanoscale, 2017,9, 5686-5693
• 3. Ester-mediated peptide formation promoted by deep eutectic solvents: a facile pathway to proto-peptides?
  Chen-Yu Chien,Sheng-Sheng Yu Chem. Commun., 2020,56, 11949-11952
• 4. Examination of ammonia–poly(pyrrole) interactions by piezoelectric and conductivity measurements
  Analyst, 1991,116, 1125-1130
• 5. Excimer emission and magnetoluminescence of radical-based zinc(ii) complexes doped in host crystals?
  Shojiro Kimura,Tetsuro Kusamoto Chem. Commun., 2020,56, 11195-11198

Professional Introduction to Compound with CAS No. 496808-01-6 and Product Name: 1-2-(Dipropylamino)ethylpiperazine

1-2-(Dipropylamino)ethylpiperazine, identified by the Chemical Abstracts Service Number (CAS No.) 496808-01-6, is a significant compound in the field of pharmaceutical chemistry and biochemistry. This piperazine derivative has garnered attention due to its unique structural properties and potential applications in drug development. The compound features a piperazine ring substituted with a dipropylaminoethyl side chain, which contributes to its distinct chemical behavior and biological activity.

The molecular structure of 1-2-(Dipropylamino)ethylpiperazine encompasses a nitrogen-rich framework, which is a hallmark of many bioactive molecules. The presence of the dipropylamino group enhances the compound's lipophilicity, making it more soluble in organic solvents and potentially facilitating its interaction with biological targets. This feature is particularly relevant in the design of drugs that require efficient absorption and distribution within the body.

Recent research has highlighted the potential of 1-2-(Dipropylamino)ethylpiperazine as a scaffold for developing novel therapeutic agents. Studies have demonstrated its ability to modulate various biological pathways, including neurotransmitter systems and inflammatory responses. The compound's structural similarity to known pharmacophores has prompted investigations into its role as an intermediate in synthesizing more complex molecules with enhanced pharmacological properties.

In the realm of medicinal chemistry, the synthesis of 1-2-(Dipropylamino)ethylpiperazine involves multi-step organic reactions that require precise control over reaction conditions. Advanced synthetic methodologies, such as catalytic hydrogenation and nucleophilic substitution, have been employed to achieve high yields and purity. These techniques ensure that the final product meets the stringent standards required for pharmaceutical applications.

The biological activity of 1-2-(Dipropylamino)ethylpiperazine has been explored in several preclinical studies. Researchers have investigated its effects on enzymes and receptors involved in pain perception, addiction, and neurodegenerative diseases. Preliminary findings suggest that this compound may exhibit potent activity in modulating these pathways, making it a promising candidate for further development into therapeutic drugs.

One of the most intriguing aspects of 1-2-(Dipropylamino)ethylpiperazine is its potential to serve as a lead compound for drug discovery programs. By leveraging computational modeling and high-throughput screening techniques, scientists can identify derivatives of this molecule that exhibit improved efficacy and reduced side effects. Such approaches are integral to modern drug development pipelines, where rapid identification of promising candidates is crucial.

The pharmacokinetic profile of 1-2-(Dipropylamino)ethylpiperazine is another critical area of study. Understanding how the compound is absorbed, distributed, metabolized, and excreted (ADME) provides essential insights into its potential therapeutic utility. Advanced analytical techniques, such as mass spectrometry and nuclear magnetic resonance (NMR) spectroscopy, have been utilized to characterize the compound's metabolic pathways and interactions with biological systems.

Future research directions for 1-2-(Dipropylamino)ethylpiperazine include exploring its role in combination therapies. By pairing this compound with other bioactive molecules, researchers aim to develop synergistic treatments that address multiple aspects of diseases simultaneously. This strategy is particularly relevant in tackling complex conditions such as cancer and neurodegenerative disorders, where multifaceted approaches are often necessary.

The regulatory landscape for pharmaceutical compounds like 1-2-(Dipropylamino)ethylpiperazine is stringent but well-defined. Compliance with guidelines set forth by agencies such as the U.S. Food and Drug Administration (FDA) and the European Medicines Agency (EMA) ensures that these compounds are safe and effective before reaching clinical use. Regulatory submissions typically involve comprehensive data on chemical synthesis, physicochemical properties, toxicology, and pharmacology.

In conclusion, 1-2-(Dipropylamino)ethylpiperazine (CAS No. 496808-01-6) represents a compelling subject of study in pharmaceutical chemistry. Its unique structural features and potential biological activities make it a valuable candidate for drug development efforts. As research continues to uncover new applications for this compound, it is likely to play an increasingly important role in the discovery and design of novel therapeutic agents.

• 7209-38-3(1,4-BIS(3-AMINOPROPYL)PIPERAZINE)
• 4553-24-6(3-(4-Propylpiperazin-1-yl)propan-1-amine)
• 50733-94-3(Piperazine, 1-propyl-,hydrochloride (1:2))
• 71888-56-7(Piperazine, 1-propyl-,hydrobromide (1:?))
• 34885-02-4(1-(3-Aminopropyl)piperazine)
• 4572-03-6(3-(4-Methylpiperazin-1-yl)propan-1-amine)
• 131922-70-8(Piperazinium,1,4-dimethyl-1-propyl-)
• 21867-64-1(1-Propylpiperazine)
• 25115-78-0(Piperazine, 1,4-dipropyl-)
• 64262-23-3(1-Propylpiperazine Dihydrobromide)